Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
November 14, 2023
Assignee:
Ra Pharmaceuticals, Inc.
Inventors:
Alonso Ricardo, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Ketki Ashok Dhamnaskar, Zhong Ma, Jonathan C. Blain, Rohit Vyasamneni
Abstract: The present invention relates to novel injectable presentations, kits or syringes comprising a composition with sustained or controlled release of lanreotide or one of the salts thereof. The compositions of lanreotide or one of the salts thereof are packaged in a syringe having a diameter greater than 3.00 mm and provided with a needle having an outer diameter no greater than 1.00 mm.
Type:
Grant
Filed:
March 28, 2019
Date of Patent:
October 17, 2023
Assignee:
EDIX SA
Inventors:
Maria Isabel Gonzalez Garcia, José Maria Roca Torrellas, Tabatha Bourgois, Laurence Lachamp, Frederic Lacombe
Abstract: Methods for the synthesis of arginine-containing peptides are provided. The methods include a deprotection step that minimizes the transfer of by-products deriving from cleaved sulfonyl-5 based side chain protecting groups from arginine to amino acids carrying electron rich side chains.
Abstract: The present invention provides the peptide nucleic acid derivative which targets 5? splice site of the human ACC2 pre-mRNA “exon 12”. The peptide nucleic acid derivatives in the present invention strongly induce splice variants of the human ACC2 mRNA in cell and are very useful to treat conditions or disorders of skin aging associated with the human ACC2 protein.
Type:
Grant
Filed:
August 5, 2019
Date of Patent:
August 29, 2023
Assignee:
OLIPASS CORPORATION
Inventors:
Seon-Young Han, Kiho Sung, Myunghyo Hong, Dayoung Kang, Jeong-Seok Heo, Kang Won Jang
Abstract: Methods for treating psychiatric and psychological diseases or conditions, including depression, by use of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin are described. The methods can be used together with other agents for treatment of depression or other psychiatric or psychological diseases or conditions. Pharmaceutical compositions comprising at least one of L-tryptophan or a derivative or analog thereof and a derivative of phyllokinin together with a pharmaceutically acceptable excipient are also described. The pharmaceutical compositions can include other therapeutically active agents for the treatment of psychiatric or psychological diseases or conditions such as depression.
Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
Type:
Grant
Filed:
October 22, 2019
Date of Patent:
August 1, 2023
Assignee:
Janssen Sciences Ireland Unlimited Company
Inventors:
Shannon Mullican, Matthew M. Rankin, Xiefan Lin-Schmidt, Chichi Huang, Jennifer Furman, Songmao Zheng, Shamina Rangwala, Serena Nelson
Abstract: An agent capable of promoting proliferation and differentiation of granulosa cells is disclosed which comprises a growth and differentiation factor-9 (GDF9) protein comprising a modified GDF9 polypeptide monomer which includes at least one amino acid substitution that enhances binding to and/or activation of activin-like kinase 4 and/or 5 receptor (ALK4/5). The agent is preferably provided in a mature dimeric form (eg comprising two monomers of the same modified GDF9 polypeptide monomer) and/or in a pro/mature complex form. The agent may be suitable for, inter alia, promoting oocyte maturation in vitro for use in assisted reproductive technologies.
Type:
Grant
Filed:
May 9, 2019
Date of Patent:
July 18, 2023
Assignee:
Monash University
Inventors:
Craig Anthony Harrison, Kelly Louise Walton
Abstract: The present disclosure is directed to hybrid multifunctional macromers that can self-assemble to form nanoparticles for on-demand and targeted release of morphogens. Embodiments of the disclosure can include the hybrid multifunctional macromers and peptide sequences incorporated therein, self-assembled nanoparticles including the hybrid multifunctional macromers, methods for producing the hybrid multifunctional macromers and peptide sequences, and methods for treating a disease by the on-demand and targeted delivery of a compound using the hybrid multifunctional macromers.
Abstract: There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutical acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.
Abstract: The present invention relates to compositions comprising fibrinogen gamma prime variants for use in the treatment or prevention of an infection and methods of administering the composition. The fibrinogen gamma prime variants in the composition comprise at least one fibrinogen gamma prime polypeptide chain. The compositions for use according to the invention may also comprise other fibrinogen variants. Compositions comprising fibrinogen gamma prime variants according to the invention improve survival time after infection up to more than 200 percent compared to WT fibrinogen. They may be used both therapeutically and prophylactically.
Type:
Grant
Filed:
March 25, 2021
Date of Patent:
June 6, 2023
Assignee:
FIBRIANT B.V.
Inventors:
Miranda Weggeman, Joseph Grimbergen, Jacob Koopman
Abstract: Disclosed herein include methods, compositions, and kits suitable for use in thresholding of protein signals. There are provided, in some embodiments, synthetic protein circuits that respond to inputs only above or below a certain threshold concentration. In some embodiments, the threshold value itself is tunable. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
June 6, 2023
Assignee:
California Institute of Technology
Inventors:
Lucy S. Chong, Ronghui Zhu, Xiaofei Ge, Michael B. Elowitz, Mark W. Budde
Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).
Type:
Grant
Filed:
July 24, 2020
Date of Patent:
May 30, 2023
Assignee:
ALS THERAPY DEVELOPMENT INSTITUTE
Inventors:
Steven Perrin, Fernando G. Vieira, Alan Gill, Theo Hatzipetros, Kyle Denton, Matvey Lukashev
Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
May 16, 2023
Assignee:
Novo Nordisk A/S
Inventors:
Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
Abstract: The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
May 9, 2023
Assignee:
Massachusetts Institute of Technology
Inventors:
Kelly Dare Moynihan, Rebecca Lynn Holden, Darrell J. Irvine, Bradley Lether Pentelute
Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
Type:
Grant
Filed:
May 3, 2019
Date of Patent:
April 25, 2023
Assignee:
Novo Nordisk A/S
Inventors:
Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard Dimarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
Abstract: The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs.
Type:
Grant
Filed:
February 22, 2019
Date of Patent:
April 25, 2023
Assignee:
LIPOTRUE, S.L.
Inventors:
Ariadna Grau-Campistany, Silvia Pastor, Patricia Carulla, Juan Carlos Escudero, Julia A. Boras, Isabel Devesa Giner, Gregorio Fernandez Ballester
Abstract: The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.
Abstract: Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.
Abstract: Described herein are Notch-modulating peptides (including monomers and multimers) capable of increasing or decreasing an immune response in a subject, compositions comprising the peptides, and methods of use thereof.
Type:
Grant
Filed:
March 26, 2018
Date of Patent:
March 28, 2023
Assignee:
Ohio State Innovation Foundation
Inventors:
Thomas J. Magliery, Mikhail M. Dikov, David Carbone, Nicholas Long, Brandon Sullivan, Elena Tchekneva
Abstract: Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an ?9-containing nicotinic acetylcholine receptor (nAChR) (e.g., the ?9?10 subtype of the nAChR) in a subject.
Type:
Grant
Filed:
January 3, 2020
Date of Patent:
March 28, 2023
Assignee:
Kineta Chronic Pain, LLC
Inventors:
Jose Mercado, Eric J. Tarcha, Jeffrey J. Posakony, Shawn Iadonato